AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14636098 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous submaximal (SUB)
Number of subjects: 16
Study 14636098 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 16
Study 14636098 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour recovery condition
Number of subjects: 16
Study 10987602 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg and 125 mg
Number of subjects: 384
Study 10987602 — intervention group
Group type: COMPARATOR
Intervention: Azimilide 50 mg
Number of subjects: 384
Study 10987602 — intervention group
Group type: COMPARATOR
Intervention: Azimilide 100 mg
Number of subjects: 384
Study 10987602 — intervention group
Group type: COMPARATOR
Intervention: Azimilide 125 mg
Number of subjects: 384
Study 8621870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened flaked corn cereal
Number of subjects: 24
Study 8621870 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsweetened flaked corn cereal
Number of subjects: 24
Study 8621870 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 24
Study 8621870 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 24
Study 1597329 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training programme for mothers
Number of subjects: 80
Study 1597329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 3085131 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (2.5, 5.0, 10, 20 mg)
Number of subjects: 0
Study 3085131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29522439 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (RV)
Number of subjects: 70
Study 26701793 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM (10 g Lacprodan PL-20, twice daily)
Number of subjects: 58
Study 26701793 — intervention group
Group type: COMPARATOR
Intervention: Control (10 g Miprodan 30, twice daily)
Number of subjects: 58
Study 25477073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 120
Study 25477073 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone
Number of subjects: 120
Study 25477073 — intervention group
Group type: COMPARATOR
Intervention: Computer
Number of subjects: 120
Study 22709382 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced group (n=11)
Number of subjects: 22
Study 22709382 — intervention group
Group type: COMPARATOR
Intervention: Inexperienced group (n=11)
Number of subjects: 22
Study 20503005 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator
Number of subjects: 40
Study 20503005 — intervention group
Group type: COMPARATOR
Intervention: Bite-jumping appliance
Number of subjects: 40
Study 18377130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dissonance (CD) intervention
Number of subjects: 188
Study 18377130 — intervention group
Group type: EXPERIMENTAL
Intervention: Media advocacy (MA) intervention
Number of subjects: 188
Study 18377130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 188
Study 15802340 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention to reduce exposure to allergens and passive smoking (n = 222)
Number of subjects: 476
Study 15802340 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 221)
Number of subjects: 476
Study 15802340 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention (n = 222)
Number of subjects: 476
Study 12182742 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy
Number of subjects: 1497
Study 12182742 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1497
Study 10350225 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaire (adapted from ECRHS)
Number of subjects: 0
Study 10350225 — intervention group
Group type: COMPARATOR
Intervention: Clinical evaluation (history, physical examination, skin prick tests, serum total IgE, phadiotop measurements)
Number of subjects: 0
Study 7669310 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with alfentanil (0.5 mcg/kg initial dose, continuous infusion 0.2 to 0.5 mcg/kg/min, self-administered 3 to 5 mcg/kg with a 5-minute lockout)
Number of subjects: 62
Study 7669310 — intervention group
Group type: COMPARATOR
Intervention: Physician-controlled analgesia with continuous infusions (0.75 mcg/kg/min) and intermittent boluses (5 mcg/kg) of alfentanil
Number of subjects: 62
Study 1836062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet (0.15 g EPA/d, 0.41 g DHA/d)
Number of subjects: 21
Study 1836062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish + Oil diet (0.99 g EPA/d, 0.99 g DHA/d)
Number of subjects: 21
Study 1836062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil alone (5 g/d for 6 weeks, 0.84 g EPA/d, 0.48 g DHA/d)
Number of subjects: 21
Study 1836062 — intervention group
Group type: COMPARATOR
Intervention: Essentially fish-free control diet
Number of subjects: 21
Study 6992909 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene)
Number of subjects: 128
Study 6992909 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study 6992909 — intervention group
Group type: COMPARATOR
Intervention: Both groups (naftidrofuryl and control)
Number of subjects: 128
Study 31603245 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month strict oral hygiene phase
Number of subjects: 44
Study 31603245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructions or motivation on oral hygiene)
Number of subjects: 44
Study 31562715 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemodiafiltration (CVVHDF)
Number of subjects: 30
Study 31562715 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous arterio-venous hemodiafiltration (CAVHDF)
Number of subjects: 30
Study 28286605 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Lactobacillus casei + inulin)
Number of subjects: 32
Study 25895747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-driven walking programme with educational material (n = 29)
Number of subjects: 58
Study 25895747 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving educational material only (n = 29)
Number of subjects: 58
Study 25895747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-driven walking programme (n = 29)
Number of subjects: 58
Study 25895747 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 58
Study 24045865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) 180 min/week (n = 16)
Number of subjects: 44
Study 24045865 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE) 180 min/week (n = 16)
Number of subjects: 44
Study 24045865 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control (C) (n = 12)
Number of subjects: 44
Study 22045826 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative colposcopy or biopsy without CIN
Number of subjects: 551
Study 22045826 — intervention group
Group type: COMPARATOR
Intervention: Routine screening at intervals of three or five years
Number of subjects: 551
Study 19900257 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D health states valuation using TTO
Number of subjects: 611
Study 19900257 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D health states valuation using VAS
Number of subjects: 611
Study 19900257 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Argentine TTO values with US values
Number of subjects: 611
Study 17986292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation (PEX) syndrome
Number of subjects: 339
Study 17986292 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-angle glaucoma (OAG)
Number of subjects: 339
Study 17986292 — intervention group
Group type: COMPARATOR
Intervention: Mortality
Number of subjects: 339
Study 15471059 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls (experimental group, n = 41)
Number of subjects: 83
Study 15471059 — intervention group
Group type: COMPARATOR
Intervention: Attention-only control (n = 42)
Number of subjects: 83
Study 11488382 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter model for word identification
Number of subjects: 0
Study 9703167 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional service by a specialist team
Number of subjects: 314
Study 9703167 — intervention group
Group type: COMPARATOR
Intervention: Existing standard services
Number of subjects: 314
Study 7994666 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg (oral administration)
Number of subjects: 3
Study 2563744 — intervention group
Group type: EXPERIMENTAL
Intervention: A single oral dose of 8.8 mg azelastine
Number of subjects: 6
Study 2563744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 197446 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (15 to 60 mg, subcutaneously administered)
Number of subjects: 0
Study 197446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31910028 — intervention group
Group type: COMPARATOR
Intervention: Lipid trial (acute feeding study)
Number of subjects: 17
Study 31910028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (+25% energy excess) (chronic study)
Number of subjects: 17
Study 31910028 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute and short-term dietary fat overload
Number of subjects: 17
Study 31565898 — intervention group
Group type: EXPERIMENTAL
Intervention: NA-XY (nalbuphine-xylazine combination: xylazine 1.1mL/100 kg IV and nalbuphine 1 mg/kg IV)
Number of subjects: 5
Study 31565898 — intervention group
Group type: COMPARATOR
Intervention: XY (xylazine 1.1mL/100 kg IV)
Number of subjects: 5
Study 29164254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (7.5 mg/d)
Number of subjects: 560
Study 29164254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 29164254 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (560 participants)
Number of subjects: 560
Study 24711046 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Family Therapy (RFT)
Number of subjects: 45
Study 24711046 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 45
Study 23644823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) - up to 1500 mg iron
Number of subjects: 26
Study 23644823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21481942 — intervention group
Group type: EXPERIMENTAL
Intervention: Short cue
Number of subjects: 123
Study 21481942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical cue
Number of subjects: 123
Study 21481942 — intervention group
Group type: COMPARATOR
Intervention: Long cue
Number of subjects: 123
Study 21481942 — intervention group
Group type: COMPARATOR
Intervention: Oblique cue
Number of subjects: 123
Study 18080768 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ulcerative colitis (UC) patients
Number of subjects: 89
Study 18080768 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Crohn's disease (CD) patients
Number of subjects: 89
Study 18080768 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 89
Study 18080768 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with disease activity markers
Number of subjects: 89
Study 17138086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 30
Study 17138086 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 30
Study 12826316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP) - gemcitabine 1200 mg/m² on days 1 and 8 plus cisplatin 80 mg/m² on day 2.
Number of subjects: 120
Study 12826316 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC) - gemcitabine 1200 mg/m² on days 1 and 8 plus carboplatin AUC=5 on day 2.
Number of subjects: 120
Study 12826316 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 120
Study 12826316 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 120
Study 10671908 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 13
Study 10671908 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 13
Study 9124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate 200 mg/m2/day and hydroxyurea 500 mg/day
Number of subjects: 14
Study 9124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate 250 mg/m2/day and hydroxyurea 1,000 mg/day
Number of subjects: 14
Study 9124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate 300 mg/m2/day and hydroxyurea 1,000 mg/day
Number of subjects: 14
Study 9124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate 350 mg/m2/day and hydroxyurea 1,000 mg/day
Number of subjects: 14
Study 9124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gallium nitrate and hydroxyurea
Number of subjects: 14
Study 8227897 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl
Number of subjects: 39
Study 8227897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 2940475 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdihydrolisuride (1 mg daily)
Number of subjects: 10
Study 31827359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat (LCHF) diet
Number of subjects: 7
Study 31827359 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat (HCLF) diet
Number of subjects: 7
Study 29424885 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter dilation (BCD)
Number of subjects: 102
Study 29424885 — intervention group
Group type: COMPARATOR
Intervention: Traditional endoscopic sinus surgery (ESS)
Number of subjects: 102
Study 26914542 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-withdrawal (n = 23)
Number of subjects: 40
Study 26914542 — intervention group
Group type: COMPARATOR
Intervention: CNI-minimization (n = 17)
Number of subjects: 40
Study 24366547 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial immune enteral nutrition
Number of subjects: 46
Study 24366547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 22241678 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 518
Study 22241678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 20447260 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft + GTR
Number of subjects: 40
Study 20447260 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 40
Study 17592099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin, vitamin E, and homocysteine lowering therapy
Number of subjects: 93
Study 17592099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 15654663 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath relaxation incisions
Number of subjects: 100
Study 15654663 — intervention group
Group type: COMPARATOR
Intervention: Conventional mass closure
Number of subjects: 100
Study 15654663 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 12680814 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-only presentation
Number of subjects: 29
Study 12680814 — intervention group
Group type: COMPARATOR
Intervention: Audiovisual presentation
Number of subjects: 29
Study 12680814 — intervention group
Group type: EXPERIMENTAL
Intervention: Story-retelling task
Number of subjects: 29
Study 12680814 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to direct questions
Number of subjects: 29
Study 10571362 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness measurement
Number of subjects: 896
Study 8964274 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate monotherapy
Number of subjects: 30
Study 8964274 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic open FBM
Number of subjects: 30
Study 8964274 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline insomnia and anxiety
Number of subjects: 30
Study 8964274 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarting original AEDs
Number of subjects: 30
Study 8964274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1845173 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon- and dentist-delivered smoking cessation intervention
Number of subjects: 186
Study 6614410 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg cimetidine orally 120 to 180 minutes prior to induction of anaesthesia
Number of subjects: 150
Study 6614410 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg cimetidine rectally in small children up to 15 kg
Number of subjects: 150
Study 6614410 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 150
Study 30411239 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding My Way (FMW) intervention
Number of subjects: 191
Study 30411239 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 191
Study 29710870 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Diet (HCD)
Number of subjects: 8
Study 29710870 — intervention group
Group type: COMPARATOR
Intervention: High-Fat Diet (HFD)
Number of subjects: 8
Study 25248661 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 84
Study 25248661 — intervention group
Group type: COMPARATOR
Intervention: Standard orthopedic nursing care (Control)
Number of subjects: 84
Study 24441952 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL (both refractive and diffractive)
Number of subjects: 21
Study 24441952 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 21
Study 24441952 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 21
Study 22293042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive behavioral intervention (3 sessions of 90 minutes each)
Number of subjects: 31
Study 22293042 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (2 months)
Number of subjects: 31
Study 21157170 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion (once a day for 15 min, at least 5 days a week for 8 weeks)
Number of subjects: 26
Study 21157170 — intervention group
Group type: COMPARATOR
Intervention: Control (no moxibustion treatment)
Number of subjects: 26
Study 17532336 — intervention group
Group type: COMPARATOR
Intervention: Cabrera's sign (notching in the ascending limb of the S wave in lead V(3), V(4), or V(5))
Number of subjects: 107
Study 17532336 — intervention group
Group type: COMPARATOR
Intervention: Chapman's sign (notching of the R wave in lead I, aVL, or V(6))
Number of subjects: 107
Study 17532336 — intervention group
Group type: COMPARATOR
Intervention: Presence of a qR in lead I, aVL, or V(6)
Number of subjects: 107
Study 17532336 — intervention group
Group type: COMPARATOR
Intervention: Notching of QRS in lead II, III, or aVF
Number of subjects: 107
Study 17532336 — intervention group
Group type: COMPARATOR
Intervention: Presence of a qR in lead II, III, or aVF
Number of subjects: 107
Study 17532336 — intervention group
Group type: EXPERIMENTAL
Intervention: All 5 ECG signs combined
Number of subjects: 107
Study 16386621 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir for the first 21 days
Number of subjects: 25
Study 16386621 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir followed by oral ganciclovir up to day 120 posttransplantation (historical control group)
Number of subjects: 25
Study 12011822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 0
Study 12011822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10348929 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective inhibitors of cyclooxygenase-2 (COX-2)
Number of subjects: 0
Study 10348929 — intervention group
Group type: COMPARATOR
Intervention: Classical NSAIDs (non-selective)
Number of subjects: 0
Study 8523145 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic analysis of theories related to aggression
Number of subjects: 0
Study 2279802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (7 mg/kg)
Number of subjects: 175
Study 2279802 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (8 mg/kg)
Number of subjects: 175
Study 7247696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg i.v. infusion)
Number of subjects: 8
Study 7247696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume and infusion speed)
Number of subjects: 8
Study 31491873 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol emulsion (1.5 g/day phytosterol equivalents)
Number of subjects: 32
Study 31491873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28322987 — intervention group
Group type: EXPERIMENTAL
Intervention: High reward condition
Number of subjects: 60
Study 28322987 — intervention group
Group type: COMPARATOR
Intervention: Standard reward condition
Number of subjects: 60
Study 27339303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 200
Study 27339303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 25466242 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg/day)
Number of subjects: 336
Study 25466242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 25466242 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 336
Study 22326642 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-ISS (2 doses at 0 and 4 weeks)
Number of subjects: 2415
Study 22326642 — intervention group
Group type: COMPARATOR
Intervention: HBV-Eng (3 doses at 0, 4, and 24 weeks)
Number of subjects: 2415
Study 19497643 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational magazine (twice monthly)
Number of subjects: 450
Study 19497643 — intervention group
Group type: COMPARATOR
Intervention: Standard health intervention (Control group)
Number of subjects: 450